Quantbot Technologies LP Sells 64,470 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quantbot Technologies LP reduced its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 89.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,881 shares of the life sciences company’s stock after selling 64,470 shares during the quarter. Quantbot Technologies LP’s holdings in Integra LifeSciences were worth $179,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in IART. Nisa Investment Advisors LLC raised its position in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares during the last quarter. Empowered Funds LLC bought a new position in Integra LifeSciences in the fourth quarter worth $180,000. Centiva Capital LP acquired a new stake in Integra LifeSciences during the third quarter worth $192,000. Dynamic Technology Lab Private Ltd bought a new stake in Integra LifeSciences in the 3rd quarter valued at $198,000. Finally, Romano Brothers AND Company acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $204,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $21.69 on Monday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.67 billion, a P/E ratio of -240.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. The firm has a 50 day moving average of $23.78 and a 200-day moving average of $22.21. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $35.45.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.89 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.